185 related articles for article (PubMed ID: 34983086)
1. Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options.
Narain TA; Sooriakumaran P
World J Mens Health; 2022 Jan; 40(1):66-73. PubMed ID: 34983086
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. PSA and beyond: alternative prostate cancer biomarkers.
Saini S
Cell Oncol (Dordr); 2016 Apr; 39(2):97-106. PubMed ID: 26790878
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer and the role of biomarkers.
Nevo A; Navaratnam A; Andrews P
Abdom Radiol (NY); 2020 Jul; 45(7):2120-2132. PubMed ID: 31720770
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers for prostate cancer: prostate-specific antigen and beyond.
Duffy MJ
Clin Chem Lab Med; 2020 Feb; 58(3):326-339. PubMed ID: 31714881
[TBL] [Abstract][Full Text] [Related]
6. Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection.
Ferrer-Batallé M; Llop E; Ramírez M; Aleixandre RN; Saez M; Comet J; de Llorens R; Peracaula R
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420168
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer biomarkers: Are we hitting the mark?
McGrath S; Christidis D; Perera M; Hong SK; Manning T; Vela I; Lawrentschuk N
Prostate Int; 2016 Dec; 4(4):130-135. PubMed ID: 27995111
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
Fradet Y
Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
[TBL] [Abstract][Full Text] [Related]
10. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
11. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
12. Five-year downstream outcomes following prostate-specific antigen screening in older men.
Walter LC; Fung KZ; Kirby KA; Shi Y; Espaldon R; O'Brien S; Freedland SJ; Powell AA; Hoffman RM
JAMA Intern Med; 2013 May; 173(10):866-73. PubMed ID: 23588999
[TBL] [Abstract][Full Text] [Related]
13. Smarter screening for prostate cancer.
Tan GH; Nason G; Ajib K; Woon DTS; Herrera-Caceres J; Alhunaidi O; Perlis N
World J Urol; 2019 Jun; 37(6):991-999. PubMed ID: 30859272
[TBL] [Abstract][Full Text] [Related]
14. Advances in the diagnostic options for prostate cancer.
French WW; Wallen EM
Postgrad Med; 2020 Dec; 132(sup4):52-62. PubMed ID: 32900250
[TBL] [Abstract][Full Text] [Related]
15. Low Levels of Urinary PSA Better Identify Prostate Cancer Patients.
Occhipinti S; Mengozzi G; Oderda M; Zitella A; Molinaro L; Novelli F; Giovarelli M; Gontero P
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298784
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of screening for prostate cancer with prostate specific antigen (PSA) in the medical checkup ("human dock") at Onomichi Municipal Hospital: clinical significance of the cases diagnosed as prostate cancer].
Oeda T; Kusumi N; Takamoto A
Nihon Hinyokika Gakkai Zasshi; 2010 Jan; 101(1):18-24. PubMed ID: 20158074
[TBL] [Abstract][Full Text] [Related]
18. Newer potential biomarkers in prostate cancer.
Wright JL; Lange PH
Rev Urol; 2007; 9(4):207-13. PubMed ID: 18231617
[TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).
Stephan C; Rittenhouse H; Hu X; Cammann H; Jung K
EJIFCC; 2014 Apr; 25(1):55-78. PubMed ID: 27683457
[TBL] [Abstract][Full Text] [Related]
20. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
